company background image
BMXM.F logo

bioMérieux OTCPK:BMXM.F Stock Report

Last Price

US$108.55

Market Cap

US$12.9b

7D

0%

1Y

1.9%

Updated

27 Mar, 2024

Data

Company Financials +

BMXM.F Stock Overview

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

BMXM.F fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance2/6
Financial Health6/6
Dividends2/6

bioMérieux S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for bioMérieux
Historical stock prices
Current Share Price€108.55
52 Week High€114.00
52 Week Low€90.23
Beta0.14
1 Month Change-4.26%
3 Month Change0.046%
1 Year Change1.92%
3 Year Change-14.19%
5 Year Change26.21%
Change since IPO192.59%

Recent News & Updates

Recent updates

Shareholder Returns

BMXM.FUS Medical EquipmentUS Market
7D0%2.2%0.4%
1Y1.9%13.3%28.8%

Return vs Industry: BMXM.F underperformed the US Medical Equipment industry which returned 12% over the past year.

Return vs Market: BMXM.F underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is BMXM.F's price volatile compared to industry and market?
BMXM.F volatility
BMXM.F Average Weekly Movementn/a
Medical Equipment Industry Average Movement7.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: BMXM.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine BMXM.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
196312,846Pierre Bouludhttps://www.biomerieux.com

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests.

bioMérieux S.A. Fundamentals Summary

How do bioMérieux's earnings and revenue compare to its market cap?
BMXM.F fundamental statistics
Market capUS$12.88b
Earnings (TTM)US$387.31m
Revenue (TTM)US$3.98b

33.3x

P/E Ratio

3.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BMXM.F income statement (TTM)
Revenue€3.67b
Cost of Revenue€1.62b
Gross Profit€2.06b
Other Expenses€1.70b
Earnings€357.60m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Sep 04, 2024

Earnings per share (EPS)3.03
Gross Margin55.99%
Net Profit Margin9.73%
Debt/Equity Ratio13.8%

How did BMXM.F perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

28%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.